智通财经网·2026-03-23 08:43Core Viewpoint - Shandong Xinhua Pharmaceutical Co., Ltd. has received approval for the registration of Ibuprofen Granules from the National Medical Products Administration, indicating a significant advancement in its product portfolio and potential market impact [1] Group 1: Company Developments - The company's wholly-owned subsidiary, Shandong Zibo Xinda Pharmaceutical Co., Ltd., has successfully obtained the drug registration certificate for Ibuprofen Granules [1] - The registration application for Ibuprofen Granules was submitted to the Center for Drug Evaluation (CDE) in December 2023 and was accepted, leading to the approval in March 2026 [1] Group 2: Product Information - Ibuprofen Granules are indicated for the relief of mild to moderate pain, including headaches, joint pain, migraines, toothaches, muscle pain, neuralgia, and dysmenorrhea, as well as for fever caused by common colds or influenza [1] - The product is classified as a Category B drug in the National Basic Medical Insurance, Work Injury Insurance, and Maternity Insurance Drug Catalog (2025 edition) [1] Group 3: Market Insights - The sales revenue for ibuprofen-related formulations in Chinese public medical institutions is projected to be approximately RMB 4.4 billion in 2024 [1]